Consumer leaflet for a Veterinary Product
This medicine is marketed according to a veterinarian's prescription only.
For animal use only

1. Name of the veterinary medicine, form and strength

CHANAZINE 10 % VETERINARY,
Solution for intramuscular or intravenous injection.

2. Active ingredient and its quantity in a dosage unit

Xylazine 100 mg/ 1ml
and preservatives:
Methylparaben 1.2 mg/ml
Propylparaben 0.8 mg/ml

A full list of excipients is detailed in section 13 – "Additional information".

3. What is the medicine intended for

A sedative with analgesic and muscle relaxant properties for use in horses only, in cases where sedation is required including:
1. Handling fractious animals e.g. for transportation.
2. Medical examinations e.g. X-ray examinations, removal of bandages; examination of the penis and oral cavity.
3. Premedication for minor superficial operations, and local or regional anaesthesia.
4. Elimination of defaecation when examining and treating the vagina, uterus and hindquarters.

Therapeutic group: Nervous system, psycholeptics, hypnotics and sedatives; xylazine
.

4. Contra-indications

Do not use in cases of known hypersensitivity to the active ingredient.
Do not administer by the intra-carotid route.
Do not use in the first trimester or the last month of pregnancy.

5. Side effects

Effects such as bradycardia, cardiac arrhythmia and polyuria may occur in the horse.
Following intravenous administration, a transient rise followed by a fall in blood pressure usually occurs.
If you notice any serious side effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.
Side effects can be reported to the Ministry of Health by clicking on the link "Adverse Drug Reactions Report" that appears on the home page of the Ministry of Health web site (www.health.gov.il), which leads to an online form for reporting side effects. Alternatively, you can use the following link: https://sideeffects.health.gov.il/

6. Target animals: Horses.

7. Dosage and administration

In horses:
Chanazine 10% Veterinary is administered by slow intravenous injection at a dose rate of 0.5-1 ml/100 kg bodyweight (0.5 - 1mg/kg) or intramuscularly at a dose rate of 1 - 2 ml/100 kg bodyweight (1 - 2 mg/kg). Animals do not usually become recumbent and light to deep sedation with a variable degree of analgesia is obtained. The principal pharmacological activities develop within 10 to 15 minutes after intramuscular administration and within 5 minutes following intravenous administration. A sleep - like state the depth of which is dose dependent is usually maintained for 1 - 2 hours, while analgesia lasts from 15 - 30 minutes.
Chanazine 10% Veterinary may be employed as a pre-medication to barbiturate anaesthesia or in combination with regional or local anaesthesia for painful surgical procedures.
When used as a pre-anaesthetic medication the dose rate of barbiturate should be reduced to a quarter to half of normal.
Nervous or excitable horses may require higher doses. Older horses and those having undergone

severe physical exertion before treatment should receive the lowest dose rate.

8. How to use the product

Chanazine 10% veterinary is given by intramuscular or intravenous administration.
Intravenous injection should be slow taking from one to two minutes .
Dosage is dependent on the degree of sedation required and the response of the animal.

9. Withdrawal period: Not relevant.

10. Warnings

Special warnings regarding the safety of use of medicine in animals
Xylazine is not an ideal sedative for caesarian section because of its oxytocic effect which impedes uterine suturing.
The use of xylazine should be carefully considered in cases of cardiac aberrations, arterial hypotension/shock and renal or hepatic impairment.
Careful consideration should be given before administering to animals exposed to stress conditions such as extreme heat, cold, high altitude or fatigue.
The usual precautions for handling animals should be observed even when a high dose of Chanazine 10 % Veterinary has been given.
Protect from hypothermia and intense heat during recovery.

Special warnings regarding the safety of the person handling the product
To the user:
In the case of accidental oral intake or self-injection, seek medical advice immediately and show the package leaflet to the doctor, but **DO NOT DRIVE** as sedation and changes in blood pressure may occur.
Avoid skin, eye or mucosal contact.
Immediately after exposure, wash the exposed skin with large amounts of fresh water.
Remove contaminated clothes that are in direct contact with skin.
In the case of accidental contact of the product with eyes, rinse with large amounts of fresh water.
If symptoms occur, seek the advice of a doctor.
If pregnant women handle the product, special caution should be observed not to self inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.
To the physician:
Xylazine is an alpha2-adrenoreceptor agonist. Symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and haemodynamic symptoms should be treated symptomatically.

Pregnancy and lactation in treated animal:
Chanazine 10% Veterinary should not be administered during the last month of pregnancy because of the risk of inducing premature parturition. As the safety of Xylazine use during organogenesis has not been fully demonstrated by current methods it should not be used during the first trimester of pregnancy.

Interactions with other medicines and other types of interactions:
Analeptics will reduce the depth, or shorten the period of sedation.

Overdose
Alpha-2-blockers such as atipamezole are effective in reversing the sedation and other physiological effects of Xylazine.

Incompatibility:
Mixing Xylazine with other agents in the same syringe is not advised.

11. Storage instructions

- Avoid poisoning! This medicine, and any other medicine, must be kept in a closed place outside the reach and sight of children and/or infants to prevent accidental poisoning.
- Do not use the medicine after its expiration date (exp. date) as it appears on the package.

The expiration date refers to the last day of the stated month.

- Storage conditions: Store below 25°C. Store in the original package and in upright position.
- Avoid the introduction of contamination during use.
- In case of any changes in product appearance such as bacterial growth or discoloration occur, the product should be discarded.

12. Instructions for disposing of the product / remaining product at the end of its use

Any unused veterinary medicinal product or waste materials derived from using veterinary medicinal product should be disposed of as toxic waste, do not throw into sewer.

13. Additional information

- In addition to the active substance, the medicine also contains: Hydrochloric acid, concentrated, Sodium citrate, Methyl Parahydroxybenzoate, Citric acid monohydrate, Propyl Parahydroxybenzoate, Water for injection.
- The medicine appearance and package content: amber glass vial containing a clear solution free from visible particles.
- Package size: 50 ml.

Manufacturer: CHANELLE PHARMACEUTICALS MANUFACTURING LTD., LOUGHREA CO. GALWAY, IRELAND

Registration holder: VETMARKET LTD., 23 HACHORESH WAY, INDUSTRIAL PARK MODI'IN REGION.

Approved in: 08/2025.

Registration number of this medicine in the Ministry of Health State Medicine Registry: 179-36-36499-99